Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio SAN DIEGO — Sodium-glucose ...

The study covered in this summary is under consideration at Cardiovascular Diabetology and was published on researchsquare.com as a preprint and has not yet been peer reviewed. Patients with type 2 ...

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

In a recent study published in the journal Signal Transduction and Targeted Therapy, researchers from Australia investigated the potential of small molecule inhibitors, specifically GSK126 (short for ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...